On April 8, 2025 Indivumed reported major milestones achieved, cementing its position as a leading oncology R&D company. Its unique, patient-centric approach to precision oncology, including data-driven AI to decipher cell biology in thousands of highly standardized cancer tissue samples, has successfully passed its proof-of-concept phase (Press release, Indivumed Therapeutics, APR 8, 2025, View Source [SID1234651833]). Numerous therapeutically novel targets and the first prototype compounds are presented, promising to significantly advance drug development in oncology. Indivumed has expanded its leadership team with Prof. Dr. Anton Wellstein as Chief Scientific Officer (CSO) and Dr. Matthias Evers as Chief Business Officer (CBO) to drive the continued growth of the company.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Unique Approach and Unmatched Data Quality
Indivumed’s unique patient-centric R&D approach to cancer research is driven by a standardized collection process with a cold ischemia time of under 10 minutes, ensuring the integrity of tissue samples and preserving therapeutic target expression. The resulting database, IndivuType, is built on over 20 years of global clinical collaboration. It combines comprehensive multi-omics including proteomics and phospho-proteomics, and longitudinal clinical data, providing unparalleled molecular insights that are critical for oncology drug discovery.
Building on a Legacy of Excellence
IndivuType is the foundation of Indivumed’s data-driven target identification and validation process. By utilizing advanced data analytics and AI algorithms Indivumed creates a holistic view of deep and multi-modal molecular data to discover therapeutically novel targets. In addition, in-house generated patient-derived 2D and 3D cellular models, closely mimicking original tumor biology, enable effective validation of targets and reduce risk in downstream drug development.
Drug discovery activities and collaborations encompass virtual and fragment-based ligand screening, hit and lead optimization, and preclinical development, aiming to advance promising candidates toward IND. In-depth knowledge of the molecular and clinical characteristics of the targeted patient population further enables the company to support tailor-made clinical trial and patient stratification strategies at an early stage.
Deep insights leading to therapeutically novel targets
The current R&D focus lies on colorectal cancer, a disease with a high unmet medical need. Indivumed’s pipeline includes a range of targets in different stages of validation and drug discovery. Discussions with potential pharmaceutical partners are ongoing to develop hit/lead molecules towards IND and into valuable precision therapeutics.